VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab

被引：43
|
作者：
Carbone, David P. [1 ]
Salmon, J. Stuart [3 ]
Billheimer, Dean [2 ]
Chen, Heidi [1 ]
Sandler, Alan [1 ]
Roder, Heinrich [4 ]
Roder, Joanna [4 ]
Tsypin, Maxim
Herbst, Roy S. [5 ]
Tsao, Anne S. [5 ]
Tran, Hai T. [5 ]
Dang, Thao P. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA
[2] Univ Utah, Salt Lake City, UT USA
[3] Carolinas Hematol Oncol Associates, Charlotte, NC USA
[4] Biodesix, Steamboat Springs, CO USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
LUNG CANCER | 2010年 / 69卷 / 03期
关键词：
Lung cancer; Erlotinib; Bevacizumab; Serum biomarker; Proteomics; Personalized therapy; ENDOTHELIAL GROWTH-FACTOR; MASS-SPECTROMETRY; CHEMOTHERAPY; COMBINATION; RECURRENT;
D O I：
10.1016/j.lungcan.2009.11.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat (R)) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat (R) could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：337 / 340
页数：4
相关论文
共 50 条
  • [1] VeriStrat predicts survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib and bevacizumab
    Salmon, J. S.
    Dang, T. P.
    Billheimer, D.
    Roder, H.
    Grigorieva, J.
    Tsypin, M.
    Herbst, R. S.
    Tsao, A. S.
    Tran, H.
    Carbone, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Predictive value of serum MALDI-TOF proteomic profiling from patients treated with erlotinib and bevacizumab for survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib alone
    Dang, T. P.
    Salmon, J. S.
    Chen, H.
    Chen, S.
    Lee, J. W.
    Sandler, A. B.
    Herbst, R. S.
    Brahmer, J.
    Carbone, D. P.
    Shyr, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] PROSPECTIVE CORRELATIVE STUDY OF FDGPET SUV AND PROTEOMIC PROFILE (VERISTRAT) OF NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH ERLOTINIB
    Lazzari, Chiara
    Tiseo, Marcello
    Gregorc, Vanesa
    Latteri, Fiorenza
    Ippolito, Massimo
    Baldari, Sergio
    Cosentino, Sebastiano
    Scarlattei, Maura
    Foti, Silvia
    Roder, Heinrich
    Bordonaro, Roberto
    Ardizzoni, Andrea
    Parra, Hector J. Soto
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1090 - S1090
  • [4] PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED ERLOTINIB/GEFITINIB WHO FAILED PREVIOUS CHEMOTHERAPY
    Madolangan, Jamaluddin
    Andarini, Sita Laksmi
    Hudoyo, Achmad
    RESPIROLOGY, 2014, 19 : 165 - 165
  • [5] ERLOTINIB AND BEXAROTENE FOR PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Dragnev, K. H.
    Seltzer, M.
    Rigas, J. R.
    DiSalvo, W. M.
    Simeone, S.
    Johnstone, D.
    Nugent, W.
    Waxman, S.
    Dmitrovsky, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [6] The association between PTEN expression and survival in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with erlotinib
    Hensing, T. A.
    Fidler, M. J.
    Wong, F.
    Polish, A.
    Watkin, W.
    Basu, S.
    Kaiser-Walters, K. A.
    Pool, M.
    Coon, J.
    Bonomi, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E)
    Villaflor, V. M.
    Kanteti, R.
    Watson, S. M.
    Karrison, T.
    Vokes, E. E.
    Salgia, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
  • [9] C-erbB-3 Expression in Non-small Cell Lung Cancer (NSCLC) Patients Treated by Erlotinib
    Cstoth, Ingrid
    Anthoine, Geraldine
    Berghmans, Thierry
    Mascaux, Celine
    Paesmans, Marianne
    Sculier, Jean-Paul
    Meert, Anne-Pascale
    ANTICANCER RESEARCH, 2011, 31 (01) : 281 - 285
  • [10] Gastrointestinal hemorrhage in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib and celecoxib.
    Fidler, M. J.
    Argiris, A.
    Patel, J. D.
    Johnson, D. H.
    Sandler, A.
    Villaflor, V.
    Coon, J.
    Buckingham, L.
    Bonomi, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 407S - 407S
12345